Compare BRX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRX | LNTH |
|---|---|---|
| Founded | 2011 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 6.6B |
| IPO Year | 2013 | 2014 |
| Metric | BRX | LNTH |
|---|---|---|
| Price | $28.00 | $99.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $31.58 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 2.6M | 835.2K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | 0.65 | ★ 2.91 |
| Revenue | ★ $1,371,597,000.00 | $343,374,000.00 |
| Revenue This Year | $5.06 | N/A |
| Revenue Next Year | $1.25 | $14.19 |
| P/E Ratio | $43.20 | ★ $34.29 |
| Revenue Growth | ★ 6.73 | 3.62 |
| 52 Week Low | $24.66 | $49.67 |
| 52 Week High | $32.86 | $111.86 |
| Indicator | BRX | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 39.50 |
| Support Level | $25.89 | $98.81 |
| Resistance Level | $31.06 | $101.24 |
| Average True Range (ATR) | 0.41 | 0.43 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 27.14 | 12.85 |
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.